Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antigen-processing machinery breakdown and tumor growth.

B Seliger1, M J Maeurer, S Ferrone

  • 1Johannes Gutenberg-University, III. Dept of Internal Medicine, Langenbeckstr. 1, 55131 Mainz, Germany. B.Seliger@3-med.klinik.uni-mainz.de

Immunology Today
|August 23, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive flow cytometric reference intervals of leukocyte subsets from six study centers across Europe.

Clinical and experimental immunology·2020
Same author

Blood immune cell biomarkers in lung cancer.

Clinical and experimental immunology·2018
Same author

Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies.

HLA·2016
Same author

c-Myc and EBV-LMP1: two opposing regulators of the HLA class I antigen presentation machinery in epithelial cells.

British journal of cancer·2012
Same author

Increased (6 exon) interleukin-7 production after M. tuberculosis infection and soluble interleukin-7 receptor expression in lung tissue.

Genes and immunity·2011
Same author

Alternative splicing of interleukin-7 (IL-7) and interleukin-7 receptor alpha (IL-7Ralpha) in peripheral blood from patients with multiple sclerosis (MS).

Journal of neuroimmunology·2010

Defects in antigen-processing machinery (APM) for both MHC class I and II are linked to cancer development. These abnormalities may help tumor cells evade T cell recognition, impacting cancer immunity.

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • Major histocompatibility complex (MHC) class I antigen-processing machinery (APM) defects are observed in various tumors.
  • Emerging murine data suggest potential roles for MHC class II APM defects in human malignant transformation.

Purpose of the Study:

  • To elucidate the pathophysiology of MHC class I and II APM.
  • To review APM abnormalities in tumor cells.
  • To discuss the implications of APM defects in tumor immune evasion.

Main Methods:

  • Literature review of pathophysiology and tumor cell APM abnormalities.
  • Analysis of existing murine data on MHC class II APM and malignant transformation.
  • Discussion of T cell recognition evasion mechanisms.

Related Experiment Videos

Main Results:

  • Pathophysiology of both MHC class I and II APM detailed.
  • APM abnormalities are a recurring feature in tumor cells across different histologies.
  • Tumor cell APM defects contribute to immune evasion from T cell recognition.

Conclusions:

  • MHC class I and II APM defects are implicated in cancer development and progression.
  • Understanding APM pathophysiology is crucial for cancer immunotherapy strategies.
  • APM abnormalities represent a significant mechanism for tumor immune escape.